India Hair Growth ​Market Report​ 2026

Hair loss is quietly moving from a pharmacy transaction to a shelf-bought category in India, and the shift is happening faster than the industry has acknowledged. The alopecia-driven hair growth market, worth USD 267 Mn in 2023, is set to more than double by 2028. Underneath the headline number, the category mix is rearranging; supplements are compounding at more than twice the pace of the topical solutions that historically built this market. 

The demand pool is structural. An estimated 82 Mn urban Indians, roughly 38% of the urban population, currently deal with hair loss. 59 Mn rely on home remedies, 16 Mn on basic retail products like shampoos and serums, only about 5 Mn use a medicated OTC product, and just 1 Mn seek clinical treatment. The conversion gap up the structured-product funnel is where the next decade of category growth sits, and across the most recent M&A cycle, consumer goods capital, both global and Indian, has moved decisively to claim it. 

What is less well understood is how the Indian consumer moves through this category, and why the current category architecture is organised around price points that sit above mass willingness to pay. 

What This Report Unpacks for Brands and Investors

• Why India is compounding faster than any major hair growth market globally, and what the worldwide shift towards supplements signals for the next phase here 

• The two strategic models that have emerged in India, and the trade-offs a BPC or FMCG entrant faces between them 

• How the recent BPC and FMCG acquisitions are redrawing the competitive map 

• The four distinct consumer cohorts are mapped, and the channel architecture for each requires 

• The BPC and FMCG fit checklist: which product formats clear the consumer, economic, distribution, and regulatory tests, and which do not 

• The real build required to convert a pharmacy-bought category into a retail-bought one 

• Evaluating whether to build, buy, or wait 

• Laying out a grounded view of where the category is consolidating, and where the scale winner is likely to emerge 

• And, evaluating whether to build, buy, or wait 

Access this report and get the Redseer sense.